The GOP’s reluctance to challenge rising prescription drug costs could be a political liability for the party in 2020.
Outrage over increasing prices has propelled the issue to the top of voters’ minds heading into the November elections, when Republicans hope to keep control of the Senate and retake the House.
But proposals that would limit what drug companies can charge for their products face opposition from Republicans, presenting an obstacle to congressional passage. Continue reading.